Inve US ▾
CVCV

CapsoVision (CV) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 13, 2026

Source: earnings call transcript

Executive summary

CapsoVision Q2 FY26 — Strong CapsoCam Plus Adoption and AI Highlights International Launch

CapsoVision reported solid Q2 FY26 results, marked by robust adoption of its CapsoCam Plus platform and the international launch of AI Highlights. The company is navigating competitive pricing and increased operating expenses while advancing its pipeline, with key regulatory milestones for AI Highlights in the US and CapsoCam Colon anticipated in the coming quarters. Management expects stronger revenue in the second half of the fiscal year.

Highlights

5

  • Delivered 10% year-over-year revenue growth to $3.6 million.

  • CapsoCam Plus patient imaging grew 23% year-over-year to over 176,000 patients worldwide.

  • Successfully launched AI Highlights commercially in the European Union and other international markets.

  • CapsoCam Plus capsule shipments increased 13% year-over-year to 8,845 units.

  • Secured key customer renewals and added new accounts, strengthening market presence.

Concerns

5

  • Gross margin declined to 51% from 55% in Q2 FY25 due to pricing pressure and higher customs/tariff expenses.

  • Operating expenses increased significantly to $9.5 million from $6.5 million in Q2 FY25, driven by R&D and public company costs.

  • FDA clearance for AI Highlights in the US is delayed to end of Q3 FY26 due to requests for additional demographic data.

  • CapsoCam Colon FDA submission shifted by a quarter to Q4 FY26, requiring more positive subjects with significant polyps.

  • Experienced approximately 3% decrease in average selling price due to competitive market pressure.

Guidance & targets

CategoryTargetConfidence
AI Highlights FDA clearance
By end of Q3 FY26
high materiality
High
AI Highlights US commercial launch
Shortly after Q3 FY26 FDA clearance
high materiality
High
CapsoCam Colon FDA submission
During Q4 FY26
high materiality
Medium
H2 FY26 Revenue
Higher than H1 FY26
high materiality
Medium
Q4 FY26 Revenue vs Q3 FY26
Stronger than Q3 FY26
medium materiality
Medium

Product announcements

ProductTypeDetails
AI Highlightslaunch

Risks & headwinds

Pricing pressure in a competitive market Q2 FY26

Approximately 3% decrease in average selling price; contributed to gross margin decline from 55% to 51%.

Mitigation:Increasing value of system by launching AI in the U.S. to help with offering.

Higher customs and tariff expenses Q2 FY26

Contributed to gross margin decline from 55% to 51%.

Mitigation:N/A (inbound tariffs from changes in U.S. trade policies earlier this year).

Delay in FDA clearance for AI Highlights in the US Q3 FY26

Expected clearance shifted to end of Q3 FY26.

Mitigation:Working closely with the agency to address requests regarding demographic representation within the clinical dataset.

Delay in CapsoCam Colon FDA submission Q4 FY26

Submission timing shifted by a quarter to Q4 FY26.

Mitigation:Need for more positive subjects with significant polyps based on discussions with the FDA; taking time to deliver a highly differentiated platform.

What to watch in Q3 FY26

AI Highlights US FDA Clearance

End of Q3 FY26
Current Pending FDA review, additional demographic data requested
Target Clearance obtained

Why it matters

FDA clearance is a critical catalyst for commercial introduction in the US, expected to drive further adoption and counter pricing pressure.

We have been working closely with the agency to address those requests and expect to obtain FDA clearance by the end of the third quarter, with commercial launch expected shortly thereafter.

Find out whether CV delivers this. Inve re-checks your case every morning.

Q&A highlights

What is the source of pricing pressure (competition vs. hospital cost-consciousness)? Are tariffs on inbound raw materials or outbound sales?

Pricing pressure is primarily from a specific competitor. The tariff impact is due to inbound raw material costs.

“So in terms of the first part of your question, the competitive pressure, yes, so we do have one particular competitor that we go up against. You know, we just see that pressure and that impacted us a little bit in the quarter. And then the second part of your question, about the tariffs, that's inbound.”

asked by Bruce Jackson · answered by David Garcia

2 min read 5 chapters

Detailed narrative

CapsoCam Plus Adoption & Utilization

CapsoVision continues to see strong adoption of its CapsoCam Plus platform, with over 176,000 patients imaged worldwide as of June 30, a 23% increase year-over-year from 143,000 patients in Q2 2025. This growth is driven by continued utilization within the existing customer base and traction with new accounts, including key renewals with major medical centers like University of Minnesota Medical Center and Henry Ford Medical Center. The platform is now the #1 capsule used in hospitals in Washington state, highlighting its value and strong customer relationships.

AI Highlights International Launch & US Outlook

The company successfully launched AI Highlights in the EU and other international markets, integrating AI analysis tools with CapsoView software and the CapsoCloud platform. These are classified as Class IIa medical devices in Europe, providing a regulatory foundation. Early customer feedback is encouraging, and the international launch is expected to provide valuable real-world experience ahead of the anticipated US commercial introduction in Q4 FY26, following expected FDA clearance by the end of Q3 FY26. This AI integration is seen as a key competitive differentiator.

CapsoCam Colon Development Progress

Development of CapsoCam Colon, a second-generation capsule with an AI module, is progressing. The FDA submission is now expected in Q4 FY26, a quarter later than initially planned, to allow for the inclusion of more positive subjects with significant polyps in the clinical dataset, based on FDA discussions. This strategic delay aims to deliver a highly differentiated platform incorporating the latest imaging technology and AI capabilities for greater long-term commercial success.

CapsoCam UGI for Pancreatic Cancer

The CapsoCam UGI clinical study, evaluating its potential for pancreatic cancer detection, is in early stages but enrollment is proceeding as planned. Management views this as a significant long-term opportunity, given the challenges of early pancreatic cancer detection and the potential for capsule endoscopy as a non-invasive diagnostic tool. This program highlights the versatility of CapsoVision's platform beyond small bowel imaging.

Financial Flexibility & Investment Strategy

CapsoVision ended the quarter with $9.1 million in cash and cash equivalents. The company raised $14 million in Q1 FY26 through a private placement and established an at-the-market (ATM) equity offering program of up to $100 million with Cantor Fitzgerald. These measures provide financial flexibility to continue investing in commercial organization, product development, and clinical programs, supporting long-term growth initiatives and advancing the pipeline.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.